经导管主动脉瓣生物瓣衰败后再行TAVR:TAV-in-TAV与TAV-in-SAV的倾向评分匹配比较
本研究基于Redo-TAVR国际注册登记数据,比较了经导管主动脉瓣衰败后行TAVR(TAV-in-TAV,434例)与外科主动脉瓣衰败后行TAVR(TAV-in-SAV,624例)的结局。经倾向评分匹配后分析330例(165:165),TAV-in-TAV的 procedural success 更高(72.7% vs 62.4%,p=0.045),而 procedural safety 及30天和1年死亡率相似。TAV-in-TAV术后主动脉瓣面积更大、平均残余压差更低,但轻度主动脉瓣反流更常见。
要点
- TAV-in-TAV的 procedural success 高于TAV-in-SAV(72.7% vs 62.4%,p=0.045)。
- 两组 procedural safety 及30天、1年死亡率无显著差异。
- TAV-in-TAV术后瓣口面积更大、残余压差更低,但轻度瓣周漏更常见。
核心结论
- 在倾向评分匹配队列中,TAV-in-TAV与更高的 procedural success 相关,且 procedural safety 和死亡率与TAV-in-SAV相似。
研究设计与样本
- 基于Redo-TAVR国际注册登记的多中心回顾性研究,纳入434例TAV-in-TAV和624例TAV-in-SAV连续病例,经倾向评分匹配后分析330例(165:165)。
主要发现
- TAV-in-TAV vs TAV-in-SAV的 procedural success 分别为120例(72.7%)和103例(62.4%)(p=0.045)。
- Procedural safety 分别为116例(70.3%)和119例(72.1%)(p=0.715)。
- 30天死亡率分别为5例(3%)和7例(4.4%)(p=0.570);1年死亡率分别为12例(11.9%)和10例(10.2%)(p=0.633)。
- TAV-in-TAV术后主动脉瓣面积更大(1.55 ± 0.5 cm² vs 1.37 ± 0.5 cm²;p=0.040),平均残余压差更低(12.6 ± 5.2 mm Hg vs 14.9 ± 5.2 mm Hg;p=0.011)。
- 中度及以上残余主动脉瓣反流发生率相似,但轻度主动脉瓣反流在TAV-in-TAV后更常见(p=0.003)。
临床怎么用
- 对于预期寿命可能超过瓣膜耐久性的主动脉瓣狭窄患者,选择初始生物瓣时应考虑后续干预的相对安全性和有效性。
- TAV-in-TAV可作为外科主动脉瓣衰败后TAVR的可行选择,但需注意轻度主动脉瓣反流更常见。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgical aortic valve replacement and transcatheter aortic valve replacement (TAVR) are now both used to treat aortic stenosis in patients in whom life expectancy may exceed valve durability. The choice of initial bioprosthesis should therefore consider the relative safety and efficacy of potential subsequent interventions. OBJECTIVES: The aim of this study was to compare TAVR in failed transcatheter aortic valves (TAVs) versus surgical aortic valves (SAVs). METHODS: Data were collected on 434 TAV-in-TAV and 624 TAV-in-SAV consecutive procedures performed at centers participating in the Redo-TAVR international registry. Propensity score matching was applied, and 330 matched (165:165) patients were analyzed. Principal endpoints were procedural success, procedural safety, and mortality at 30 days and 1 year. RESULTS: For TAV-in-TAV versus TAV-in-SAV, procedural success was observed in 120 (72.7%) versus 103 (62.4%) patients (p = 0.045), driven by a numerically lower frequency of residual high valve gradient (p = 0.095), ectopic valve deployment (p = 0.081), coronary obstruction (p = 0.091), and conversion to open heart surgery (p = 0.082). Procedural safety was achieved in 116 (70.3%) versus 119 (72.1%) patients (p = 0.715). Mortality at 30 days was 5 (3%) after TAV-in-TAV and 7 (4.4%) after TAV-in-SAV (p = 0.570). At 1 year, mortality was 12 (11.9%) and 10 (10.2%), respectively (p = 0.633). Aortic valve area was larger (1.55 ± 0.5 cm2 vs. 1.37 ± 0.5 cm2; p = 0.040), and the mean residual gradient was lower (12.6 ± 5.2 mm Hg vs. 14.9 ± 5.2 mm Hg; p = 0.011) after TAV-in-TAV. The rate of moderate or greater residual aortic regurgitation was similar, but mild aortic regurgitation was more frequent after TAV-in-TAV (p = 0.003). CONCLUSIONS: In propensity score-matched cohorts of TAV-in-TAV versus TAV-in-SAV patients, TAV-in-TAV was associated with higher procedural success and similar procedural safety or mortality.
引用
- Landes U, Sathananthan J, Witberg G, et al. Transcatheter Replacement of Transcatheter Versus Surgically Implanted Aortic Valve Bioprostheses. J Am Coll Cardiol. 2021. PMID: 33413929. doi:10.1016/j.jacc.2020.10.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。